Ondansetron sustained-release - Adare Pharmaceuticals

Drug Profile

Ondansetron sustained-release - Adare Pharmaceuticals

Alternative Names: EUR-1025

Latest Information Update: 04 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eurand
  • Developer Adare Pharmaceuticals
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Nausea and vomiting

Highest Development Phases

  • No development reported Nausea and vomiting

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top